Honorhealth Research Institute
Scottsdale, Arizona 85260
36 studies enrolling now · 162 studies all time
What they study most
ALS, Acid Reflux, Acute Lymphocytic Leukemia, Acute Myeloid Leukemia, Acute Non-cardioembolic Ischemic Stroke, Adenocarcinoma, Adenocarcinoma of Pancreas, Adenovirus Infection, Adult Solid Tumor, Advanced Cancer, Advanced Malignancy, Advanced Pancreatic Cancer
Studies at this site
- A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors — Recruiting now
- A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer — Recruiting now
- SW-682 in Advanced Solid Tumors — Recruiting now
- OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events — Recruiting now
- A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7) — Recruiting now
- Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab — Recruiting now
- A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies — Recruiting now
- Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors — Recruiting now
- A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis — Recruiting now
- A Study to Test the Safety and Tolerability of SBO-154 in Patients With Advanced Solid Tumors. — Recruiting now
- Pancreatic Cancer Early Detection Consortium — Recruiting now
- Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma — Recruiting now
- Dabrafenib and/or Trametinib Rollover Study — Recruiting now
- A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors — Recruiting now
- A Study of PYX-201 in Advanced Solid Tumors — Recruiting now
- A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG. — Recruiting now
- SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma — Recruiting now
- Pancreatic Cancer Detection Consortium (PCDC) Prospective Cohorts — Recruiting now
- Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas — Recruiting now
- A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) — Recruiting now
- Study of DT-7012 as a Single Agent and in Combination With an Immune Checkpoint Inhibitor in Participants With Advanced Solid Tumors — Recruiting now
- A U.S. Pilot Human Investigation of RadiofrEquency Vapor Ablation System to Evaluate Safety, TOleRability, and Effectiveness for Proximal Intestinal Mucosal Ablation in Patients With Type 2 Diabetes Mellitus (RESTORE-1 Study) — Recruiting now
- Efficacy of the COronary SInus Reducer in Patients With Refractory Angina II — Recruiting now
- Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors — Recruiting now
- Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer — Recruiting now
- Acoustic Cluster Therapy (ACT) With Chemotherapy for the Treatment of Locally Advanced Pancreatic Cancer — Recruiting now
- Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors — Recruiting now
- A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies — Recruiting now
- A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation — Recruiting now
- ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors — Recruiting now
- Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors — Recruiting now
- Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis — Recruiting now
- A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs — Recruiting now
- Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067 — Recruiting now
- Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies — Recruiting now
- SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN — Running, not enrolling
- Trial of Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) — Completed
- Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia — Completed
- An Investigation of the EndoStim® Lower Esophageal Sphincter (LES) Stimulation System for the Treatment of Reflux — Stopped early
- Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Hydroxychloroquine as Treatment in Untreated Pancreas Cancer — Completed
- Open-Label Extension Study of Setmelanotide — Completed
- A Phase 1 Study of SYNCAR-001 + STK-009 Without Conditioning Chemotherapy (Lymphodepletion) in Subjects With Severe, Refractory Systemic Autoimmune Rheumatic Disease — Running, not enrolling
- Hand Therapy Intervention Versus Traditional Occupational Therapy to Prevent Chemotherapy Induced Peripheral Neuropathy — Completed
- Evaluation of Revumenib in Participants With Colorectal Cancer and Other Solid Tumors — Stopped early
- An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors — Completed
- Avelumab Program Rollover Study — Running, not enrolling
- A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors — Running, not enrolling
- A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors — Starting soon
- ORB-011 In Patients With Advanced Solid Tumors — Completed
- PRO1107 in Patients With Advanced Solid Tumors — Stopped early